Compositions and methods for treating obesity and hyperphagia
AssigneeMetrohealth Ventures LLC
InventorsM. Michael Wolfe, Michael O. Boylan
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to the treatment of diseases or conditions characterized by the buildup of fatty tissue, or hyperphagia, such as Prader-Willi syndrome, obesity, metabolic syndrome, type II diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered. This results in a reduced rate of weight gain, weight loss, and/or reduction in fatty tissue, and a marked decrease in lipid synthesis and accumulation.
Claims20
A method of treating obesity in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising a pharmaceutically effective amount of an antibody means for binding to and inhibiting gastric inhibitory polypeptide (GIP) signaling and a IgG1, IgG2, IgG3, or IgG4 heavy chain constant region, wherein the pharmaceutical composition is administered once a week, twice a month, once a month, or less frequently.
A method of treating obesity in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of an anti-GIP antibody, wherein the anti-GIP antibody is administered once a week, twice a month, once a month, or less frequently;
- wherein the anti-GIP antibody comprises a light chain variable domain and a heavy chain variable domain, wherein the light chain variable domain comprises a first complementarity determining region (CDR) comprising the amino acid sequence of SEQ ID NO:
- 20, a second CDR comprising the amino acid sequence of SEQ ID NO:
- 21, and a third CDR comprising the amino acid sequence of SEQ ID NO:
- 22;
- and wherein the heavy chain variable domain comprises a first CDR comprising the amino acid sequence of SEQ ID NO:
- 31, a second CDR comprising the amino acid sequence of SEQ ID NO:
- 32 or SEQ ID NO:
- 34, and a third CDR comprising the amino acid sequence of SEQ ID NO:
- 33.
Dependencies are inferred from the claim text.